We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Cloudy, GC has already stated that he will be recruiting within investor relations.
Investor relations is important for maintaining relations with existing investors and also building confidence for new investment.
Some of these subjects are ambiguous, as proven by this message board and it will be beneficial to have someone solely concentrated on IR to provide definitive answers to our questions.
Not long to wait before questions can be asked with next Group Investor Call on the 10th August
https://www.linkedin.com/events/nasdaq-tlsa-tizianalifesciences6823287607246516224/
I reckon Tils will float around £3 mark when trial starts and escalate as MS and Alzheimer’s news comes in let alone milciclib in Asian market and news of IL6 mab which was accelerated comes in.
I would not want to be out of this at this level. But hay takes allsorts.
As someone said GC has turned down offers, May be said offerers have sour grapes .
We are in phase 2 for everything foralumab Tils wants to try, as long as safety trials are undertaken, which they have.IMO
MS trial is phase 2 , we are well in phase2 now so as that graph showed we are worth well over $500mill so what’s happening????
To be fair ROCKZ why would they do that, all the info is out there so it seems a bit pointless, Why should they care about shareholders who haven’t a clue what there invested in , no offence. They got loads a money ,enough to see them through this, good or bad I see this as make or break, yes it will be a few months maybe a year but Tils is still here.
Exactly Bluebelly, when Tils got the license for foralumab is was Phase2 asset from novimmune.
I think because it was IV administered it had some unwarranted side effects, no one died, but I think they gave up, and a while ago I was researching mabs and foralumab was in list but use was unknown, I think tils has found a use now as different methods of administration and a lot low dose seems to be sweet. Rock on !!!
Maybe the first trial will be classed as Phase 2a and the second trial Phase 2b?
The sooner someone is appointed to the specific role of investor relations the better.
Questions like this will be cleared up.
Good to see Foralumab being listed on the clinical trials website though.
Agree Cloudy - From Link:
'In a separate Phase 2 randomized, controlled, pilot trial conducted to assess safety, tolerability, and efficacy in 39 patients with mild to moderate COVID-19 in Brazil, showed that intranasal foralumab may be of benefit in modulating immune reactivity and in reducing pulmonary inflammation. Importantly, intranasal administration of foralumab was well tolerated with no clinically significant changes in blood cell counts (including blood lymphocytes), no evidence of hypersensitivity, and no serious adverse events (SAEs) were reported in the study.'
BB
We are well into Phase 2 now, foralumab is a Phase 2 asset and with confirmation first Brazil trial was Phase 2 our MC should be over $500mill.
Who was it said first Brazil trial was not a proper trial, it was phase 2 as stated!!
Amazing news thanks bigjohnny.!!
https://clinicaltrials.gov/ct2/show/NCT04983446?spons=tiziana&draw=2&rank=1
At least there's only 5 months of 2021 left.
BB
Thanks for that info vic960
Shame it's not starting until 25th Oct with study completion date of May 2022.
Is this because they wanted more data on Foralumab as stated by SJ1.
Hopefully the SPA data from the MS patient will give us a lift.
BB
ClinicalTrials.gov Identifier: NCT04983446
Recruitment Status : Not yet recruiting
First Posted : July 30, 2021
Last Update Posted : July 30, 2021
Official Title: A Phase 2 Proof-of-concept Study to Evaluate the Safety, Tolerability, and Efficacy of Intranasal Foralumab in Hospitalized Subjects With Severe COVID-19 and Pulmonary Inflammation
Estimated Study Start Date : October 25, 2021
Estimated Primary Completion Date : February 25, 2022
Estimated Study Completion Date : May 30, 2022
https://newsfilter.io/articles/in-patient-covid-19-study-of-intranasal-foralumab---nct04983446-56056afa8adad10bca6ac6c97ec930b2